Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-01-19-Speech-3-354-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-01-19"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"el"^^xsd:language2
lpv:document identification number	"en.20110119.20.3-354-000"2
lpv:hasSubsequent	lp_eu:2011-01-19-Speech-3-355-0002
lpv:speaker	lp:Nikolaos Chountis2
lpv:spokenAs	member; Delegation for relations with Albania, Bosnia and Herzegovina, Serbia, Montenegro and Kosovo (2009-09-16--2014-06-30)3 member; ECON (2009-07-16--2012-01-18)3 unknown; Coalition of the Radical Left (2009-07-14--2014-06-30)3 substitute; AFET (2009-07-16--2012-01-18)3 member_of_the_bureau; EUL/NGL (2009-07-14--2014-06-30)3 member; Special Committee on the Financial, Economic and Social Crisis (2009-10-08--2011-07-31)3 substitute; Delegation to the EU-Russia Parliamentary Cooperation Committee (2009-09-16--2014-06-30)3 substitute; Delegation to the EU-Ukraine Parliamentary Cooperation Committee (2009-09-16--2014-06-30)3 substitute; SEDE (2009-07-16--2012-01-18)3
lpv:translated text	"I voted in favour of the report on a European initiative on Alzheimer’s disease, because the European Commission and the governments of the Member States undertake to introduce European and national action plans to: promote research at European level into the causes, prevention and treatment of Alzheimer’s disease and to increase funding for it; to improve prevention and early diagnosis; to organise information campaigns for the general public, in order to improve the ability to recognise the symptoms of the disease; to recognise the heavy burden on carers of patients with dementia and to provide psychological support for patients and their families. However, the most important thing is to safeguard and promote a public approach to the disease overall. Publicly funded research, prevention, treatment and support for patients and their families and relatives is important not just in principle. This public approach is needed in order to avoid speculation by pharmaceutical companies and other private interests. The Member States need to provide the necessary government funded services and infrastructures, so that the health and social consequences on patients and their environment can be addressed."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph